Our Work

Researchers at the Institute for Behavioral Health have been conducting analyses on various aspects of the opioid crisis since the 1990s—much longer than it’s been in the headlines.

That work is primarily divided into two main areas: prevention and treatment. As IBH Director Constance Horgan says, “We believe that dealing with the opioid crisis requires focusing across the continuum, from prevention all the way through treatment, because the situation is getting worse and we need to be more vigilant in changing the conversation if we want to succeed.”


Presentations and Events

  • Peter Kreiner served as an expert panelist at an FDA-sponsored public workshop, “Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting: A Scientific Discussion of Present and Future Capabilities,” on July 10 and 11, 2017. Along with experts from the FDA, CDC, NIDA, SAMHSA, DHHS & national research universities, participants engaged in a scientific discussion about the challenges in using the currently available data and methods for assessing the impact of opioid formulations with properties designed to deter abuse on opioid misuse, abuse, addiction, overdose, and death in the postmarket setting, as well as ways to improve the analysis and interpretation of existing data and opportunities and challenges for collecting and/or linking additional data to improve national surveillance and research capabilities in this area.
  •  “The Opioid Crisis – A Critical Threat Across The U.S. Why Health Services Research Matters session was presented at the Academy Health 2017 Annual Research Meeting in  New Orleans, LA, June 25-27, 2017. This session was co-sponsored by the Opioid Policy Research Collaborative and the Brandeis-Harvard NIDA Center to Improve the System Performance of Substance Use Disorders at the Institute for Behavioral Health. Panel members: Andrew Kolodny, MD, Peter Kreiner, PhD, Sharon Reif, PhD (Brandeis) and Richard Frank, PhD (Harvard).